Loading company financials…
NYSE · Surgical & Medical Instruments & Apparatus · CIK 0000010795
$184.74
-2.52% · delayed 15 min
$52.73B market value
What this company does
BECTON DICKINSON & makes medical devices and equipment. It took in $21.84B last year, which makes it a large company. Of every dollar it sells, about 8 cents is left as profit.
Financial health
Generally healthy, with a few things to watch.
From BECTON DICKINSON & CO's FY2025 annual filing · share price scored separately
Every check behind the three models, and what each one tests
Measured against FY2024, from the 10-K
Improved: +8.2%
$20.18B to $21.84B
Deteriorated: -14.4%
$3.12B to $2.67B
Deteriorated: -62.7%
$1.72B to $641.0M
It makes a profit rather than burning through money.
$1.68B earned last year
Day-to-day operations generate real cash, not just accounting profit.
$3.43B cash from operations
Nothing in the filings stands out as a concern.
Filter by minute, hour, day or week
Loading price history…
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
The growth rate someone buying today is paying for, against what the company has delivered
At today's price, the market is paying for free cash flow to grow by about 9% a year for the next 10 years. Over the last 10 years it grew by about 9% a year.
The essentials
Each answered from the filings, with the numbers behind it.
Yes. It keeps about 8 cents of every dollar of sales as profit, earning $1.68B last year.
What it earns, what it keeps, and what it costs to run — all from the same filing
Whether the dividend is covered by what the business actually earns
It pays out 71 cents of every dollar of profit and keeps the rest, which leaves the payment comfortably covered. It paid out 35% of the cash its operations generated. It has paid in each of the last 12 years.
GoodNext payment expected around , projected from how regularly it has paid before rather than from a date the company has announced.
Figures from the FY2025 annual filing
Last year it earned $1.68B and generated $3.43B of cash from operations.
Reported annual figures
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Estimated from how often this has happened before, not a confirmed date.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
Go deeper
Every figure above traces back to one of these filings.
Straight from SEC EDGAR — the original source for every figure above
| Filing | Filed | Covers to |
|---|---|---|
| Quarterly report(10-Q) | 2026-08-06 | 2026-06-30 |
| Major event announcement(8-K) | 2026-08-06 | 2026-08-06 |
Financial figures are from BDX's 10-K for fiscal year 2025 (period ending 2025-09-30), reported under the US GAAP taxonomy. View the source filing. Total liabilities were not tagged directly and were calculated as assets minus equity.
6 of 9 checks passed
Nine yes-or-no tests of whether this year's finances improved on last year's.
2.05
In the grey zone
For this model, above 2.99 is safe and below 1.81 is distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
-2.64
Below the threshold — nothing unusual flagged
Scores above -1.78 are the ones the model associates with earnings manipulation.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2025 filing as filed with the SEC.
Improved: -1.3%
289.1M to 285.4M
5 other measures barely moved. Figures compare the two most recent annual filings — read the latest one. Nothing here reads the management commentary, which is where a company explains its own numbers.
Discounted at 8%–10% a year, with growth settling to 2.5% after 10 years. Those rates are ordinary choices, not measurements: across that range the assumed growth works out between 7% and 12%. This describes what the price implies — it is not a forecast, and not a view on whether the price is right.
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 3.3% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
Slowly. Sales grew 8.2% last year.
Manageable, but notable. Clearing its debt would take about 5.4 years of cash flow. For every $1 it owes, it owns $1.85 in assets.
Expensive. Investors pay $31.4 for every $1 of yearly profit, so a lot of future growth is already priced in.
Nothing unusual. Its accounting patterns look like those of companies that report earnings straightforwardly.
At a glance
| Major event announcement(8-K) | 2026-07-22 | 2026-07-19 |
| Major event announcement(8-K) | 2026-05-29 | 2026-05-29 |
| Major event announcement(8-K) | 2026-05-20 | 2026-05-20 |
| Major event announcement(8-K) | 2026-05-12 | 2026-05-11 |
| Quarterly report(10-Q) | 2026-05-07 | 2026-03-31 |
| Major event announcement (amended)(8-K/A) | 2026-05-07 | 2025-10-09 |
| Major event announcement(8-K) | 2026-05-07 | 2026-05-07 |
| Major event announcement(8-K) | 2026-04-29 | 2026-04-28 |
| Major event announcement(8-K) | 2026-04-09 | 2026-04-06 |
| Major event announcement(8-K) | 2026-04-02 | 2026-04-02 |
| Major event announcement(8-K) | 2026-02-25 | 2026-02-25 |
| Major event announcement(8-K) | 2026-02-10 | 2026-02-10 |
| Quarterly report(10-Q) | 2026-02-09 | 2025-12-31 |
| Major event announcement(8-K) | 2026-02-09 | 2026-02-09 |
| Major event announcement(8-K) | 2026-02-09 | 2026-02-09 |
| Major event announcement(8-K) | 2026-02-05 | 2026-01-30 |
| Major event announcement(8-K) | 2026-02-05 | 2026-02-05 |
| Major event announcement(8-K) | 2026-01-30 | 2026-01-27 |
Coverage from the last 30 days
How Is Becton, Dickinson and Company's Stock Performance Compared to Other Medical Devices Stocks?
Yahoo Finance ·
Becton Dickinson (BDX) Becomes Founding Sponsor Of Hazardous Drug Data Consortium
Yahoo Finance ·
Four Industry Sponsors Commit $100,000 to Launch the Medicinal Hazard Data Standardization Consortium
Yahoo Finance ·
BD Extends Leadership in Advanced Tissue Regeneration Through Continued Clinical Innovation
Yahoo Finance ·
BD to Present at Wells Fargo 21st Annual Healthcare Conference
Yahoo Finance ·
Waters' Q4 Guide Conservative, 2027 Growth Could Reach High Single Digits, RBC Says
Yahoo Finance ·
Becton Dickinson (BDX) Completes PREVENT Trial Enrollment For Hernia Prevention Mesh
Yahoo Finance ·
BAX Raises 2026 Outlook as Strong Q2 Growth Offsets Margin Pressure
Yahoo Finance ·
How Much Upside Can BSX Stock's Growth Deliver?
Yahoo Finance ·
The Wide Divide Priced Into Boston Scientific Stock
Yahoo Finance ·
The Peer-Group Mispricing Sitting On BSX Stock
Yahoo Finance ·
Two Recessions Couldn’t Stop These 4 Healthcare Stocks From Raising Dividends
Yahoo Finance ·
Primary sources and further research